

Research

Open Access

## Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants

Patricia S Fletcher, Gregory S Wallace, Pedro MM Mesquita and Robin J Shattock\*

Address: Centre for Infection, Department of Cellular and Molecular Medicine, St George's, University of London, London, UK

Email: Patricia S Fletcher - pflerche@sgul.ac.uk; Gregory S Wallace - gwallace@sgul.ac.uk; Pedro MM Mesquita - pmesquit@sgul.ac.uk; Robin J Shattock\* - shattock@sgul.ac.uk

\* Corresponding author

Published: 01 August 2006

Received: 18 January 2006

Retrovirology 2006, 3:46 doi:10.1186/1742-4690-3-46

Accepted: 01 August 2006

This article is available from: <http://www.retrovirology.com/content/3/1/46>

© 2006 Fletcher et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Heterosexual intercourse remains the major route of HIV-1 transmission worldwide, with almost 5 million new infections occurring each year. Women increasingly bear a disproportionate burden of the pandemic, thus there is an urgent need to develop new strategies to reduce HIV-1 transmission that could be controlled by women themselves. The potential of topical microbicides to reduce HIV transmission across mucosal surfaces has been clearly identified, and some agents are currently under evaluation in clinical trials. Many of these "first generation" microbicides consist of polyanionic compounds designed to interfere with viral attachment. Here we have evaluated two candidate polyanion compounds in clinical trials, PRO 2000 and dextrin sulphate (DxS) to determine their safety and efficacy against *in vitro* HIV-1 and HSV-2 infection using cellular and tissue explant models.

**Results:** PRO 2000 and DxS potently inhibited infection by HIV-1 X4 and R5 isolates when present during viral exposure. However PRO 2000 required 10-fold and DxS 2000-fold more compound to block infection with R5 virus than X4. While both compounds were virucidal for X4 HIV-1, neither was virucidal for R5 virus. PRO 2000 efficiently inhibited infection of cervical explants and dissemination of virus by migratory DC. DxS was less active, able to completely inhibit cervical explant infection, but providing only partial reduction of virus dissemination by DC. PRO 2000, but not DxS, also inhibited HIV-1 binding to DC-SIGN<sup>+</sup> cells and *trans* infection of co-cultured target cells. The inflammatory potential of both compounds was screened by measurement of cytokine production from cervical explants, and statistically significant increases were only observed for IL-1 $\beta$  and RANTES following treatment with PRO 2000. Both compounds also demonstrated potent activity against HSV-2 infection of cervical epithelial cells.

**Conclusion:** Our results demonstrate that PRO 2000 is a potent inhibitor of R5 HIV-1 infection and dissemination pathways in human cervical explants. DxS, while demonstrating significant inhibition of R5 infection, was less active against DC mediated dissemination pathways. PRO 2000 has now entered human phase III efficacy trials.

## Background

The continuing HIV/AIDS epidemic highlights the need for additional effective methods of prevention. Such methods include the development of topically applied microbicides designed to prevent vaginal HIV-1 transmission. Large-scale efficacy trials for five products, involving tens of thousands of women and tens of millions of dollars, are either planned or are already underway [1]. Three of these products (PRO2000, Carraguard, and Cellulose sulphate) are anionic polymers and inhibit HIV-1 infection by preventing virus-cell fusion/attachment [1-3], predominantly through charge-based interactions with the V3 loop of gp120 [4-6]. Despite working through similar mechanisms, entry of these products into efficacy trials has proceeded without side-by-side preclinical assessment to determine their relative efficacy and safety. In addition, Viva Gel (SPL7013, a sulphated dendrimer), thought to work through similar mechanisms, has been entered in early phase I safety trials [7]. The fourth product in phase III trials is a buffering gel (BufferGel) containing polyanionic carbopol, whilst the fifth is based on the novel surfactant C31G (termed SAVVY) [8].

Here we describe the side-by-side preclinical evaluation of two anionic candidates, PRO 2000 and dextrin sulphate (DxS), prior to selection for phase III efficacy trials by the Microbicide Development Programme (MDP-UK). PRO 2000 is a synthetic naphthalene sulphonate polymer (average molecular weight approximately 5 kDa). Early observations suggested binding to CD4 and the V3 region of gp120, blocking subsequent interaction between CD4 and gp120 [9,10] and preventing infection of T lymphocytes, macrophages and cervical explant tissue [9-12]. More recent investigations using surface plasmon resonance (SPR) have suggested gp120 binding may be less dependent upon V3 charge, however they confirm that PRO2000 prevents viral entry [13]. Additional studies have suggested that high concentrations of a polynaphthalene sulphonate (5 mg/ml) can induce gp41 six helix bundle formation [6] rendering the virus non-infectious. DxS is a synthetic sulphated polysaccharide (average molecular weight approximately 20 kDa), whose antiviral activity is distinct from related dextran sulphate [14-16]. Early studies suggested that DxS binds strongly to tat, and weakly to gp160/120 [17,18]. However, more recent structure function-studies have demonstrated that the predominant activity of DxS is mediated through binding to gp120, regulated by the degree of polymer sulphation and V3 loop charge [15]. Thus, like PRO2000, DxS targets viral entry and both have been shown to inhibit a diverse panel of HIV isolates *in vitro* [16-18]. Furthermore, PRO 2000 and DxS have shown varying levels of protection against a SHIV-89.6 vaginal challenge in the rhesus macaque model [19,20].

We have evaluated both candidates to determine their potential selectivity against R5 and X4 HIV-1 using *in vitro* cell based assays. In addition, the activity of these compounds has been tested in a human cervical explant culture model [12,21] to determine efficacy against both localized infection and dissemination of virus by migratory cells.


## Results

### **Differential activity of polyanion microbicides towards X4 and R5 HIV-1**

Direct virucidal activity was assessed by compound treatment of immobilised virus, prior to washing and culture with permissive T cells as previously described [22]. Both compounds demonstrated potent activity against the X4 isolate, with 50% inhibitory concentrations ( $IC_{50}$ ) observed at 14.8 ( $\pm$  1.9) and 9.3 ( $\pm$  2.1)  $\mu$ g/ml of PRO 2000 and DxS respectively (Figure 1Ai & 1Bi). In contrast, both compounds failed to exert any effect against R5 virus, even at concentrations of 1 mg/ml (Figure 1Ai & 1Bi). Receptor mediated blockade was assessed by incubating target cells with compound prior to compound removal and culture with immobilised virus; this was poor or absent for both compounds (Figure 1Aii & 1Bii). Inhibition of attachment/fusion was assessed by pre-treatment of virus with test compound for 1 hour prior to culture with permissive cells in the presence of compound. Both compounds exhibited potent activity against R5 and X4 infection, although greater activity was observed against X4 than R5 virus with  $IC_{50}$  values of 1.9 ( $\pm$  1.6) and 20.8 ( $\pm$  1.5)  $\mu$ g/ml respectively for PRO 2000, and 0.38 ( $\pm$  1.9) and 782.8 ( $\pm$  2.4)  $\mu$ g/ml respectively for DxS (Figure 1Aiii & 1Biii).

### **Toxicity of polyanions towards female genital mucosal tissue cultured ex vivo**

Before the activity of compounds against HIV-1 infection of female genital tissue was investigated, it was important to ensure that neither compound would elicit a toxic effect. This was evaluated using genital mucosal tissue explants obtained from seronegative women undergoing therapeutic hysterectomy as previously described [12,21]. Tissue explants were immersed in test compound for 2 or 24 hours and tissue viability determined using the principle of MTT dye reduction (see Methods). Compounds were tested to a maximal concentration of 1 mg/ml and toxicity was compared to the known toxic agent Nonoxonyl-9 (N9) [23]. Only mild toxic effects were observed with both PRO 2000 and DxS following 2 hour compound treatment, with 50% toxic doses ( $TD_{50}$ ) of greater than 1 mg/ml for both compounds (Figure 2A and 2B). This was in contrast to N9, which caused significant toxicity with a  $TD_{50}$  of 700 ( $\pm$  2)  $\mu$ g/ml following a 2 hour treatment period (Figure 2C). In fact, N9 caused significant toxicity at 1 mg/ml, causing a 65% reduction in viability.

**Figure 1**

**Inhibitory effect of polyanionic compounds against HIV-1 infection of T-cells.** HIV-1 BaL (R5, ■, solid line) or RF (X4, □, dotted line) was immobilised onto solid phase using anti-HLA-DR antibody capture, as described in the Methods. (i) Direct virucidal activity was determined by the pre-treatment of immobilised virus for 1 hour before culture with target PM-1 cells in the absence of compound. (ii) Receptor mediated blockade activity was determined by the pre-treatment of target PM-1 cells (1 hour) prior to exposure to immobilised virus in the absence of compound. (iii) Attachment/fusion inhibition was determined by the pre-treatment of immobilised virus with test compound prior to the addition of target PM-1 cells in the presence of compound. Plates were cultured for 10 days following which viral replication was determined by reverse transcriptase measurement of culture supernatants. Compounds tested were: A) PRO 2000; and B) Dextrin sulphate. Data represent the mean  $\pm$  SEM of  $n = 5$  (PRO 2000) or 4 (Dextrin sulphate) independent experiments where each condition was tested in triplicate. Inserted figures represent the mean  $\pm$  SEM concentration inhibiting 50% infection ( $IC_{50}$ ) for compounds against each virus.


Furthermore, 24 hour treatment of tissue with N9 caused significant damage ( $TD_{50} = 34 \pm 1 \mu\text{g/ml}$ ), whilst only mild toxicity was observed following 24 h treatment with either PRO 2000 or DxS ( $TD_{50} > 1 \text{ mg/ml}$ ).

#### **Inhibition of HIV-1 infection of human cervical tissue and dissemination of virus by migratory cells**

The potential of PRO 2000 and DxS to block infection of the female genital mucosa was investigated using ectocervical explants, cultured in a non-polarised manner as previously described [21,22]. Explants were treated with test compound (PRO 2000 or DxS) for 1 hour prior to exposure to R5 HIV-1<sub>BaL</sub> for 2 hours in the presence of compound as described in the Methods. Viral infection was evaluated by p24 released into culture supernatants. The activity of polyanions against HIV-1<sub>BaL</sub> infection of cervical explants was dose-dependent (Figure 3). Both PRO 2000 and DxS were able to completely inhibit infection at 1 mg/ml ( $p < 0.001$ ), but allowed breakthrough of infec-

tion to occur at 100  $\mu\text{g/ml}$ , with DxS being 10 fold better than PRO 2000 with an  $IC_{50}$  of 6.9 ( $\pm 1.6$ ) versus 79.5 ( $\pm 3.7$ )  $\mu\text{g/ml}$  (Figure 3i).

We have previously shown spontaneous migration of CD4<sup>+</sup> dendritic cells (DC) from cervical explant tissue during overnight culture, a population of cells able to bind virus via mannose C-type lectin receptors (MCLR) and/or CD4 [21]. Migratory cells were harvested from explant cultures (exposed to compound and virus as described) following overnight culture, washed to eliminate cell free virus, and co-cultured with permissive PM-1 T cells. The effect of both compounds in preventing dissemination of virus by these migratory cells was dose-dependent. PRO 2000 completely inhibited viral transfer at 1 mg/ml, and demonstrated significant inhibition (>90%) at 100  $\mu\text{g/ml}$ , with an  $IC_{50}$  of 29.1 ( $\pm 2.5$ )  $\mu\text{g/ml}$  (Figure 3Aii). DxS provided 95% protection at 1 mg/ml (Figure 3Bii) demonstrating an  $IC_{50}$  of 62.4 ( $\pm 2.9$ )  $\mu\text{g/ml}$ .

**Figure 2**

**Toxic effects caused to cervical tissue following compound treatment.** Ectocervical explants were exposed to compounds for 2 or 24 hours. Explant viability was then determined using the principle of MTT dye reduction as described in the Methods section. % viability was calculated per mg tissue comparing compound-treated explants to unexposed controls. Compounds tested were A) PRO 2000; B) Dextrin sulphate; and C) Nonoxynol-9. Data represent the mean  $\pm$  SEM of *n* = 4 (PRO 2000), 2 (Dextrin sulphate) or 7 (Nonoxynol-9) independent donors where each condition was tested in triplicate. Inserted figures represent the mean  $\pm$  SEM 50% toxic dose (TD<sub>50</sub>) following compound treatment for 2 (● solid line) or 24 (□ dotted line) hours.


#### **Inhibition of HIV-1 binding to DC-SIGN and transfer to permissive cells**

Having observed that both compounds showed some efficacy against dissemination of HIV-1 by migratory cells, subsequent experiments were carried out to determine whether either compound blocked DC-SIGN binding and/or transfer. To this end, Raji-DC-SIGN<sup>+</sup> CD4<sup>-</sup> cells were incubated with candidate polyanions during exposure to virus (2 h). Excess virus and compound were removed by washing and cells either directly lysed to determine the amount of virus bound to cell surface receptors, or cultured with permissive T cells (PM-1) to assess *trans* infection. Mannan, the natural ligand for DC-SIGN and other MCLR, blocked most, but not all, binding of virus to Raji DC-SIGN<sup>+</sup> cells. Viral binding to Raji DC-SIGN<sup>+</sup> cells in the presence of mannan (100 μg/ml) mirrored values seen with Raji DC-SIGN<sup>-</sup> cells (Figure 4), indicating a low level (20% of untreated controls) of DC-SIGN-independent binding of virus to Raji cells. PRO 2000 exhibited significant activity at 0.25 mg/ml against virus binding to DC-SIGN and *trans* infection of PM-1 cells (Figure 4A). DxS exhibited a lower level of inhibition, demonstrating a maximal 50% inhibition of both binding and *trans* infection at the highest concentration of 2.5 mg/ml (Figure 4B) while demonstrating no statistically significant effect at lower concentrations when compared to untreated controls (taken as 100%).

#### **Effects on pro-inflammatory cytokine response in human cervical tissue**

To investigate whether exposure of human cervical tissue to candidate polyanions would elicit an inflammatory response, tissue explants were exposed to compound (2

h) prior to compound removal by washing and overnight culture. Culture supernatant was assessed by Bioluminex assay for the presence of a panel of 9 cytokines (IL-1β, IL-6, IL-8, TNF-α, GM-CSF, MIP-1α, MIP-1β, RANTES, and MCP-1). Untreated tissue explants produced detectable levels of all cytokines except TNF-α and RANTES, which were towards the limits of detection. Treatment with either compound (1 mg/ml) had little or no effect on the production of most of the cytokines including IL-6, IL-8, GM-CSF, and MIP-1α (data not shown). However, treatment with 1 mg/ml of either PRO 2000 or DxS resulted in a 13 or 6 fold (respectively) increase in IL-1β release (Figure 5i), which was statistically significant (*p* = 0.006) for PRO 2000. Both compounds also induced increases in TNF-α and RANTES production (Figure 5ii and 5iii) although only the increase in RANTES induced by PRO 2000 reached statistical significance (*p* = 0.002). To aid the interpretation of this data, results were compared with explants treated with an equal dose of the toxic compound N9. Unfortunately, N9 caused significant ( $\geq 50\%$ ) toxicity to tissue at concentrations of  $\geq 100$  μg/ml. Although approximately 50% viability was still observed at 100 μg/ml, the effect such toxicity had on cytokine release could not be determined with complete confidence, therefore only concentrations causing no toxicity were used for comparison. In general, treatment of tissue with 10 μg/ml N9 caused little change in cytokine release. To determine whether there was any correlation between increasing compound dose and release of cytokines, data was analysed using Spearman rank correlation and significance determined using two-tailed significance testing of paired samples. However, none of the compounds demonstrated any significant correlation between increasing

**Figure 3****Polyanion inhibition of HIV-1<sub>BaL</sub> infection of cervical explants and transfer of virus from migratory cells.**


Ectocervical explants were exposed to HIV-1<sub>BaL</sub> for 2 hours in the presence of test compound. Following overnight culture, explants were separated from any cells that had migrated from the tissue and cultured separately. (i) Infection of cervical explants was determined by ELISA measurement of p24 antigen in culture supernatants. (ii) Migratory cells were co-cultured with permissive T cells (PM-1) and infection determined by p24 antigen in culture supernatants. Data represent the % HIV-1 infection observed following compound treatment when compared to tissue exposed to virus alone. Each compound was tested using  $n = 3 - 8$  independent donors, where each condition was tested in triplicate. Compounds tested were A) PRO 2000 and B) Dextrin Sulphate. Inserted figures represent the mean  $\pm$  SEM concentration inhibiting 50% HIV-1 infection ( $IC_{50}$ ) for each compound. Statistical analysis was completed using student's T-test with statistically significant changes marked \* ( $p < 0.05$ ), or \*\*\* ( $p < 0.005$ ).

compound dose and modulation of cytokine release, suggesting the observed cytokine release was unlikely to reflect adverse response to compound treatment.

**Inhibition of HSV-2 infection of vaginal epithelial cells**

Due to the strong correlation reported between the presence of genital herpes and HIV-1 transmission [24], the effect of both PRO 2000 and DxS on the ability of HSV-2

to infect vaginal epithelial cells was investigated using the ME180 cell line. ME180 cells were exposed to HSV-2 (1 hour) in the presence of test compound and, following compound removal, cells were cultured for 48 hours in the absence of compound and virus, and viability determined by the principle of MTT dye reduction (see Methods). PRO 2000 and DxS demonstrated no significant toxicity towards ME180 cells, and both compounds dem-

**Figure 4**

**Inhibition of HIV-1 binding and transfer through DC-SIGN by polyanions.** DC-SIGN<sup>+</sup> Raji cells were treated with test compound (A) PRO 2000 or B) Dextrin Sulphate for 1 hour prior to exposure to HIV-1 (i) RF or (ii) BaL for 2 hours in the presence of compound. Following removal of excess compound and virus, cells were either lysed for analysis by p24 ELISA to determine inhibition of viral binding (■), or co-cultured with permissive T cells (PM-1) to determine inhibition of viral transfer (▒). Background binding to Raji cells was determined using Raji/DC-SIGN<sup>-</sup> cells, or 100 µg/ml mannan. Data represent the mean ± SEM of 3 independent experiments (except PRO 2000 against RF, where n = 2) where each condition was tested in triplicate. Statistical analysis was completed using student's T-test with statistically significant changes marked \* (p < 0.05), \*\* (p < 0.01) or \*\*\* (p < 0.005). ND = not determined.


onstrated potent anti-HSV-2 activity, with IC<sub>50</sub> values of 11.5 (± 1.4) µg/ml (PRO 2000) and 5.2 (± 1.4) µg/ml (DxS) (Figure 6).

## Discussion

Successful microbicides will need to prevent all potential mechanisms of mucosal HIV transmission. Whilst blockade of cell surface receptors (CD4, CCR5 and CXCR4) within the mucosa may prevent localised infection of T cells and macrophages, viral uptake and dissemination by DC occurs through CD4 and MCLRs [21]. Thus, preventing HIV-1 infection is highly likely to require compounds able to block viral attachment via multiple cell surface receptors. Furthermore, as HIV-1 transmission has been

associated with the presence of other sexually transmitted infections (STIs) [24] such as HSV-2, it may be useful for a topical compound to possess the ability to block such infections. Here we have evaluated the potential of two anionic polymers, PRO 2000 and DxS, to inhibit these different pathways

In agreement with previous studies [9-18], we have demonstrated that PRO 2000 and DxS potently inhibited infection by both X4 and R5 isolates of HIV-1 when present during viral exposure in cell based *in vitro* assays (Figure 1). Interestingly, these products demonstrate similar *in vitro* activity to Viva gel (SPL7013) being fast tracked for clinical trials [7]. However PRO 2000 required




**Figure 5**

**Stimulation of inflammatory cytokines in cervical tissue treated with polyanions.** Tissue explants were exposed to PRO 2000 (■), Dextrin Sulphate (□) or Nonoxynol-9 (■) for 2 hours prior to compound removal by washing and overnight culture in the absence of compound. Culture supernatants were assessed (using the Bioluminex assay) for the presence of the cytokines: A) IL-1β; B) TNF-α; and C) RANTES. Data represent the mean ± SEM for 3 individual donors. Statistical analysis was completed using student's T-test with statistically significant changes marked \*\*\* (p < 0.005). ND = Not determined. Toxic = Compound treatment caused >50% reduction in tissue viability.

10-fold and DxS 2000-fold more compound to block infection with R5 virus than X4 (Figure 1iii), confirming previous studies demonstrating differential activity against these viral phenotypes [13,17]. In addition, pre-

treatment of cells with either compound failed to provide any cellular protection. These observations confirm that activity is not mediated by steric hindrance following binding to CD4 as first thought [9,14], but through bind-



**Figure 6**

**Inhibitory effect of polyanionic compounds against HSV-2 infection of epithelial cells.** ME180 cells (seeded at  $1.5 \times 10^4$  cells/well and cultured overnight), were exposed to HSV-2 ( $\sim 5 \times 10^4$  Pfu/well) in the presence of compound for 1 hour, or alternatively, exposed to compound alone. Following compound/virus removal by washing, cells were cultured for a further 48 hours when viability was determined by MTT dye reduction. Cell viability (○, dotted line) following compound treatment was calculated as a percentage of the viability of cells exposed to culture medium alone. The effect of compound treatment on the infectivity of HSV-2 (●, solid line) was calculated as a percentage of infection observed in cells exposed to virus alone. Compounds tested were: A) PRO 2000; and B) Dextrin sulphate. Data represent the mean ± SEM of 3 independent experiments where each condition was tested in triplicate. Inserted figures represent the mean ± SEM concentration inhibiting 50% HSV-2 infection (IC<sub>50</sub>) or concentration causing 50% toxicity (TD<sub>50</sub>) towards ME180 cells.

ing with gp120, preventing subsequent receptor/co-receptor interaction [4]. While V3 charge may not be the predominant factor regulating binding *per se* of polyanions to gp120 [13], this does not negate previous observations that inhibition itself is mediated by electrostatic interaction with the gp120 V3 loop [4,17]. Competition by polyanions for these sites is more efficient the greater the envelope charge, with X4 isolates being more highly basic (>5+) than R5 isolates (2–5+) [17,25]. This is likely to account for the differential activity of the polyanions seen against X4 and R5 virus in the presence of compound. Furthermore, while both exhibited direct virucidal activity against X4 virus when pre-treated with compound, neither was virucidal for R5 virus at the concentrations tested (1 mg/ml). Such differential activity suggests that X4 isolates could be inactivated by anionic polymers within the vaginal lumen, while R5 virus would require compound to reach target cells within the mucosa with equal efficiency as the virus itself [26]. It is unclear whether the observed virucidal activity against X4 virus was mediated by induction of gp41 six-helix bundle formation. Previous studies demonstrated that 5 mg/ml polynaphthalene sulphonate was required to induce six-helix bundle formation in both X4 and R5 virus [6]. In this study we have evaluated the ability of both compounds against R5 HIV-1BaL as this virus, unlike many primary strains, provides reproducible infection of cervical tissue explants. However, PRO2000 and DxS have shown similar activity against a range of primary stains in different cellular and tissue models [11-13,15,17], suggesting that these results may predict activity against a wider range of virus stains. Interestingly, formulated PRO2000 gel performed similarly to Viva Gel (SPL7013) and better than Carraguard when tested at a single dose against primary strains in a comparable cervical explant model [11].

In contrast, microbicides based on anionic polymers have only been tested against X4 SHIV (SHIV-89.6) in the rhesus macaque vaginal challenge model [19,20]; SHIV 89.6 has sufficient charge to be inactivated by direct electrostatic interaction with polyanions in the vaginal lumen. However, as R5 virus is predominantly associated with HIV transmission [27,28], it will be important to evaluate the efficacy of such compounds against R5 virus (e.g. SHIV-162p) [29], particularly as they will need to cross the mucosa and reach target cells as efficiently as the virus itself. It is unlikely that such high molecular weight compounds can be absorbed across intact cervicovaginal epithelium and this is reflected by lack of detectable systemic toxicity [29,30] and adsorption [31] following vaginal application in human phase I trials. However, an intact stratified epithelium also provides a significant barrier to HIV-1 transmission [12], and infection is most likely associated with epithelial microtrauma [32,33]. It is anti-

ciated that such epithelial damage would also facilitate sufficient penetration of compound to protect localized susceptible cells. To test this hypothesis we have used a non-polarized explant culture system where virus and compound access all potential susceptible cells within the epithelium and underlying mucosa, such as would be the case if a breach to the mucosal surface were to occur.

In the absence of any significant toxicity (Figure 2), both PRO 2000 and DxS inhibited HIV-1 infection of cervical explant tissue, when exposed to virus in the presence of compound, with DxS providing better protection than PRO 2000. We also investigated the effects of both compounds on virus dissemination by DC that spontaneously migrate out of cervical explants. Although both compounds reduced transfer of virus by migratory cells with similar IC<sub>50</sub> values, only PRO 2000 was able to completely prevent transfer at 1 mg/ml (Figure 3Aii). It was not possible to determine whether *trans* infection of co-cultured T cells was due to uptake of virus by MCLR in the absence of DC infection, or dependent upon prior *cis* infection of DC themselves. Recent studies have suggested that *trans* infection of T cells, independent of DC infection occurs with decreasing efficiency over the first 4–24 hours, while *cis* infection of the DC occurs 24–72 hours following virus exposure [34,35]. Thus in our model it is likely that amplification of virus from migratory DC harvested following overnight culture (approximately 18 hours) occurs through a mixture of both mechanisms.

To determine whether either compound directly affected virus binding to DC-SIGN, parallel experiments were carried out using DC-SIGN<sup>+</sup> Raji cells. At 0.25 mg/ml PRO 2000 inhibited both X4 and R5 virus binding to DC-SIGN and also *trans* infection of co-cultured indicator T cells by cell bound virus (Figure 4A). These data suggest that PRO 2000 can block binding to DC-SIGN and/or that sufficient compound remains associated with the cells (or virus) to prevent bound virus being transferred to susceptible T cells. In contrast DxS failed to provide complete inhibition of either virus binding or *trans* infection at the highest dose tested (2.5 mg/ml). These data are in agreement with results obtained from the cervical DC experiments described above and suggest that DxS may be less efficient at preventing HIV dissemination by migratory DC.

Having determined the efficacy of both compounds at non-toxic concentrations in the above models, we then investigated the potential of either compound to elicit pro-inflammatory cytokine production in human cervical tissue. Only increases in IL-1 $\beta$  and RANTES, following exposure to PRO 2000, reached statistical significance. Although IL-1 $\beta$  release has been linked with adverse effects associated with topical application of N9 [36], levels of production reported here showed no significant correla-



tion with increasing compound dose. In fact, inflammatory tissue damage caused by topical application of N9 has been associated with an increase in IL-8 release [36], which was not observed with either PRO 2000 or DxS in this study. Thus these data are unlikely to reflect the occurrence of an adverse response to compound application *in vivo*. Nevertheless, in some (but not all) human phase I clinical trials, mild adverse events were more common with topical application of 4% PRO 2000 than 2% and 0.5% formulations of PRO 2000 [30,37].

In addition to demonstrating anti-HIV activity, it would be advantageous for a microbicide product to demonstrate activity against other STIs. Both PRO 2000 and DxS demonstrated potent activity against HSV-2 infection of cervical epithelial cells with similar efficacy, in agreement with previous reports for PRO 2000 against HSV-2 infection of human endocervical cells [38] or cervical epithelial (CaSki) cells [39]. These data are similar to those reported for Viva Gel (SPL7013) [40], suggesting no competitive advantage for this second generation polyanion. Furthermore, previous reports have suggested that formulated PRO 2000 (0.5% gel) retained *in vitro* anti-viral activity against both HIV-1 and HSV-2 following *in vivo* intravaginal application [39], whilst the 4% gel protected against *in vivo* HSV-2 infection in the cotton rat model [41].

Although formulated concentrations of PRO 2000 and DxS are higher than those required to prevent infection *in vitro*, they are highly likely to be diluted following vaginal application through product leakage prior to intercourse and on mixing with seminal and vaginal secretions. Based on infectivity data derived from the *ex vivo* cervical explant model, formulated PRO 2000 could be diluted 1/200 (2%) or 1/50 (0.5%) before being reduced below its protective range (100 µg/ml). However, for protection against viral dissemination by DC, this would be reduced to 1/20 (2%) or 1/5 (0.5%). In contrast, DxS while preventing cervical explant infection at a dose equivalent to a 1/40 dilution of the 4% formulation, failed to provide complete protection against DC mediated viral dissemination at the highest dose tested.

## Conclusion

In conclusion, these data demonstrate that PRO 2000 and DxS are active against R5 virus in cellular and tissue models. How these *in vitro* results will translate into *in vivo* efficacy is not yet known. The Microbicides Development Programme (UK) has elected to evaluate both 2% and 0.5% PRO 2000 gel in human phase III efficacy trials. In addition, 0.5% PRO 2000 gel will be evaluated by the HIV Prevention Trials Network (Protocol HPTN 035).

## Methods

### Cell culture and reagents

PM-1 (AIDS reagent project, National Institute for Biological Standards and Control, Potters Bar (NIBSC), UK), Raji, Raji/DC-SIGN (provided by V N Kewal-Ramani, HIV Drug Resistance Program, NCI, Frederick, MD) and Vero cells were grown in complete RPMI [RPMI 1640 medium supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine]. The adherent cell line ME180 was cultured in DMEM supplemented as complete RPMI (complete DMEM). All cells were grown in continual culture in a humidified environment of 5% CO<sub>2</sub> at 37°C and passaged every 3–4 days.

HIV-1 strains (HIV-1<sub>BaL</sub> and HIV-1<sub>RF</sub>, AIDS reagent project, NIBSC, UK) were grown in phytohaemagglutinin (PHA)-stimulated peripheral blood mononuclear cells as previously described [12]. Cell-free viral stocks were passed through 0.2 µm pore-size filters. Infection was monitored by viral p24 antigen (HIV-1 p24 ELISA, AIDS Vaccine Program, National Cancer Institute (NCI) at Frederick, MD, USA), carried out according to manufacturers protocol) or reverse transcriptase (RT) [42] release into culture supernatants. The 50% tissue culture infectious dose (TCID<sub>50</sub>) was determined in PM-1 cells for both viruses, and additionally in PHA-stimulated PBMC for HIV-1<sub>BaL</sub>.

HSV-2 (G) (kindly donated by Dr. B. Herold (Mount Sinai School of Medicine, NY, USA)) was grown in Vero cells. Infectivity of viral stocks was assessed by plaque assay using ME180 cells as previously described [43].

Unformulated PRO 2000 was provided by Indevus Pharmaceuticals, USA, and DxS by ML Laboratories, UK. Both products were used at non-toxic concentrations as determined by MTT viability assays.

### Solid-phase immobilisation of HIV-1

Solid phase immobilisation of HIV was carried out as previously described [22]. In brief, HLA-DR Mab (L243, ATCC) was bound to 96 well, flat bottom, tissue culture plates (Nunc) for 1 hour at room temperature. Unbound antibody was washed off with 1 volume PBS prior to the addition of virus (RF or BaL, 10<sup>3</sup> tissue culture infectious doses [TCID<sub>50</sub>] as determined in PM-1 cells). Plates were centrifuged for a minimum of 1 hour (room temperature) at 3200 rpm. Unbound virus was washed away with 2 volumes of PBS. Direct virucidal activity was determined by compound pre-treatment of immobilised virus for 1 hour before culture with target cells (PM-1 cells, 4 × 10<sup>4</sup> cells/well) in the absence of compound (compound was removed with 4 PBS washes). Receptor mediated blockade activity was determined by the pre-treatment of target cells (1 hour) prior to exposure to immobilised virus in

the absence of compound (where compound was removed from treated cells by 4 PBS washes). Attachment/fusion inhibition was determined by the pre-treatment of immobilised virus with test compound prior to the addition of target cells in the presence of compound. Plates were cultured for 10 days, in the absence of media (or compound) replenishment, when viral replication was determined by measurement of RT in culture supernatants. The described assay allows topical administration of candidate compounds: previous studies have demonstrated no difference in compound activity against virus that is either in suspension or immobilised onto plastic (data not shown).

#### **DC-SIGN binding and transfer assay**

To determine whether compounds blocked either virus binding and/or transfer via DC-SIGN, CD4<sup>+</sup>-DC-SIGN<sup>+</sup> or CD4<sup>+</sup>-DC-SIGN<sup>-</sup> Raji cells ( $0.5 \times 10^4$  cells/well) were treated with test compound for 1 hour at 37°C prior to exposure to virus (HIV-1<sub>RF</sub> or HIV-1<sub>BaL</sub>,  $10^4$  TCID<sub>50</sub> determined in PM-1 cells) for 2 hours at 37°C in the presence of compound. Compound and unbound virus were removed by washing (4 volumes PBS) and cells either: i) lysed in 1% Triton X-100 to determine the level of virus bound to the cell surface (p24 ELISA); or ii) co-cultured with permissive T cells (PM-1 cells,  $4 \times 10^4$  cells/well) to evaluate *trans* infection. Co-cultures were assessed for viral replication by measurement of reverse transcriptase activity following 7 days in culture.

#### **Culture and HIV infection of human genital tract tissue explants**

Cervical explant culture was performed as previously described [12,21,22]. Cervical tissue was obtained from women undergoing planned therapeutic hysterectomy (with written consent as per approval from the local Research Ethics Committee). Cervical tissue comprising both epithelium and stromal tissue was cut into 3 mm explants prior to culture submerged in RPMI 10%. Briefly, explants were pre-treated for 1 hour with test compound prior to exposure to HIV-1<sub>BaL</sub> ( $10^3 - 10^5$  TCID<sub>50</sub> determined in PHA-activated PBMC) for 2 hours at 37°C. After incubation with infectious virus and compound, explants were washed with 4 volumes of PBS. Explants were then cultured overnight prior to transfer to fresh plates and further culture for 12–14 days, with 50% media feeds every 2–3 days. Migratory cells present in the overnight culture plate were washed with 2 volumes of PBS and then co-cultured with  $4 \times 10^4$  PM-1 cells/well to assess blockade of virus transfer by migrating cells. At the end of the assay, HIV-1 infection was determined by the measurement of p24 in culture supernatants (ELISA): supernatants from explant cultures were assessed using Beckman Coulter p24 ELISA (lower detection limit of 15 pg/ml); supernatants from migratory cell co-cultures were analysed with the less

sensitive p24 ELISA from NCI (lower detection limit 300 pg/ml).

#### **Determination of compound toxicity**

Viability of cells and tissue was determined following compound treatment by the principle of MTT (3 [4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide or thiazolyl blue) dye reduction.

##### *i) Cellular toxicity*

Following compound treatment (or exposure to HSV-2, see below), ME180 cells were washed and exposed to 0.5 mg/ml MTT in complete DMEM for 2–3 hours. Cells were then solubilised in 98% isopropanol with 2% 2N HCl, and the absorbance at 570 nm determined.

##### *ii) Tissue toxicity*

Following compound treatment, cervical explants were washed (3 volumes PBS) before submersion in 200 µl MTT (0.5 mg/ml) in complete RPMI for 2–3 hours. Tissue was then blotted to remove excess liquid and tissue weight determined. Explants were transferred into 1 ml methanol and incubated overnight at room temperature in the dark. The absorbance of the MTT-formazan product was determined at 570 nm and the percentage viability per mg tissue calculated by comparing test samples to untreated explants.

#### **Cytokine detection by multiplex bead immunoassay**

Cytokine production was determined by multiplex bead immunoassays (Biosource International Inc., UK) as per manufacturers instructions. Tissue explants were exposed to compound for 2 hours prior to compound removal by washing and overnight culture in the absence of compound. Culture supernatant (50 µl) was assessed for the presence of a panel of 10 cytokines (IL-1β, IL-6, IL-8, TNF-α, GM-CSF, MIP-1α, MIP-1β, RANTES, and MCP-1). Lower limits of detection for each cytokine were generally: IL-1β (7 pg/ml), IL-6 (8 pg/ml), IL-8 (8 pg/ml), TNF-α (6 pg/ml), GM-CSF (16 pg/ml), MIP-1α (15 pg/ml), MIP-1β (19 pg/ml), RANTES (23 pg/ml) and MCP-1 (30 pg/ml). Spiked control samples demonstrated that culture conditions and any residual compound did not interfere with assay sensitivity (data not shown). Plates were read using the Luminex 100 system (Luminex Corp., USA) and data analyzed using Bioplex Manager version 4.0 software (Biorad, UK). Cytokine concentrations present in culture supernatants were determined using non-linear regression analysis.

#### **HSV-2 infectivity reduction assay**

ME180 cells ( $1.5 \times 10^4$  cells/well) were seeded in 96-well plates and cultured overnight. Cells were exposed to test compound alone (to determine compound toxicity), or virus (approximately  $5 \times 10^4$  pfu/well) in the presence of

compound (to determine inhibitory effects of the compound) for 1 hour. Compound and unbound virus was removed by washing (3 × 200 µl PBS) and cells cultured in fresh media for 48 hours. Viability was then determined by MTT assay. Whilst a decrease in cell viability in wells exposed to virus reflects viral replication, a reduction in viability following exposure to compound alone indicates toxicity. Viability and infectivity values were calculated as percentage of viability from cells exposed to culture medium alone or percentage of infectivity from cells exposed to virus in the absence of compound.

### Statistical analyses

50% inhibitory concentration analysis was determined using non-linear regression analysis, whilst correlation coefficients were calculated by non-parametric correlation (Spearman) and two-tailed p-value calculation (GraphPad PRISM, GraphPad Software, Inc.). Student's T-tests were performed in Excel (Microsoft Corporation).

### Competing interests

The author(s) declare that they have no competing interests.

### Authors' contributions

PSF participated in the design of the study, carried out anti-viral determinations in cellular and tissue models, determined the pro-inflammatory cytokine response in cervical tissue, completed any statistical analyses and helped draft the manuscript. GSW carried out DC-SIGN based experiments whilst PMMM completed anti-HSV-2 testing of compounds. RJS conceived of the study, participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

### Acknowledgements

This work was funded by Microbicide Development Programme (MDP) grant (G0100137) from the MRC and Department for International Development UK. We thank Carrie Victor-Smith for co-ordination and collection of tissue samples, and the Obstetrics and Gynaecology, and Pathology Departments of St George's, Kingston and St Helier's hospital for their assistance in obtaining cervical tissue.

### References

- Weber J, Desai K, Darbyshire J: **The development of vaginal microbicides for the prevention of HIV transmission.** *PLoS Med* 2005, **2(5)**:e142.
- Baba M, Snoeck R, Pauwels R, de Clercq E: **Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus.** *Antimicrob Agents Chemother* 1988, **32(11)**:1742-1745.
- Bagasra O, Whittle P, Heins B, Pomerantz RJ: **Anti-human immunodeficiency virus type I activity of sulfated monosaccharides: comparison with sulfated polysaccharides and other polyions.** *J Infect Dis* 1991, **164(6)**:1082-1090.
- Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, Zhao L, Olson W, Kwong PD, Sattentau QJ: **Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type I gp120.** *J Virol* 2000, **74(4)**:1948-1960.
- Callahan LN, Phelan M, Mallinson M, Norcross MA: **Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type I without interfering with gp120-CD4 interactions.** *J Virol* 1991, **65(3)**:1543-1550.
- Neurath AR, Strick N, Li YY: **Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides.** *BMC Infect Dis* 2002, **2**:27.
- McCarthy TD, Karellas P, Henderson SA, Giannis M, O'Keefe DF, Heery G, Paull JR, Matthews BR, Holan G: **Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention.** *Mol Pharm* 2005, **2(4)**:312-318.
- D'Cruz OJ, Uckun FM: **Clinical development of microbicides for the prevention of HIV infection.** *Curr Pharm Des* 2004, **10(3)**:315-336.
- Rusconi S, Moonis M, Merrill DP, Pallai PV, Neidhardt EA, Singh SK, Willis KJ, Osburne MS, Profy AT, Jensen JC, Hirsch MS: **Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type I activities.** *Antimicrob Agents Chemother* 1996, **40(1)**:234-236.
- Profy AT, Van A Rugg MR, Wang Y: **Molecular evaluation of the anti-HIV activity of PRO a candidate topical microbicide.** *XIII International AIDS conference: 2000; Durban, South Africa* 2000.
- Dezzutti CS, James VN, Ramos A, Sullivan ST, Siddig A, Bush TJ, Grohskopf LA, Paxton L, Subbarao S, Hart CE: **In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type I transmission.** *Antimicrob Agents Chemother* 2004, **48(10)**:3834-3844.
- Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ: **Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides.** *J Virol* 2000, **74(12)**:5577-5586.
- Scordi-Bello IA, Mosoian A, He C, Chen Y, Cheng Y, Jarvis GA, Keller MJ, Hogarty K, Waller DP, Profy AT, Herold BC, Klotman ME: **Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action.** *Antimicrob Agents Chemother* 2005, **49(9)**:3607-3615.
- McClure MO, Moore JP, Blanc DF, Scotting P, Cook GM, Keynes RJ, Weber JN, Davies D, Weiss RA: **Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro.** *AIDS Res Hum Retroviruses* 1992, **8(1)**:19-26.
- Shaunak S, Gooderham NJ, Edwards RJ, Payvandi N, Javan CM, Baggett N, MacDermot J, Weber JN, Davies DS: **Infection by HIV-1 blocked by binding of dextran 2-sulphate to the cell surface of activated human peripheral blood mononuclear cells and cultured T-cells.** *Br J Pharmacol* 1994, **113(1)**:151-158.
- Javan CM, Gooderham NJ, Edwards RJ, Davies DS, Shaunak S: **Anti-HIV type I activity of sulfated derivatives of dextrin against primary viral isolates of HIV type I in lymphocytes and monocyte-derived macrophages.** *AIDS Res Hum Retroviruses* 1997, **13(10)**:875-880.
- Shaunak S, Thornton M, Teo I, Chandler B, Jones M, Steel S: **Optimisation of the degree of sulfation of a polymer based construct to block the entry of HIV-1 into cells.** *J Drug Target* 2003, **11(7)**:443-448.
- Watson K, Gooderham NJ, Davies DS, Edwards RJ: **Interaction of the transactivating protein HIV-1 tat with sulphated polysaccharides.** *Biochem Pharmacol* 1999, **57(7)**:775-783.
- Weber J, Nunn A, O'Connor T, Jeffries D, Kitchen V, McCormack S, Stott J, Almond N, Stone A, Darbyshire J: **'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo.** *Aids* 2001, **15(12)**:1563-1568.
- Lewis MG, Wagner W, Yalley-Ogunro J, Greenhouse J, Profy AT: **Efficacy of PRO 2000 gel in a macaque model for vaginal HIV transmission.** *Microbicides: 2002; Antwerp, Belgium* 2002.
- Hu Q, Frank I, Williams V, Santos JJ, Watts P, Griffin GE, Moore JP, Pope M, Shattock RJ: **Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue.** *J Exp Med* 2004, **199(8)**:1065-1075.
- Fletcher P, Kiselyeva Y, Wallace G, Romano J, Griffin G, Margolis L, Shattock R: **The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type I infec-**

- tion of human cervical tissue and dissemination by migratory cells.** *J Virol* 2005, **79(17)**:11179-11186.
23. Beer BE, Doncel GF, Krebs FC, Shattock RJ, Fletcher PS, Buckheit RW Jr, Watson K, Dezzutti CS, Shummins JE, Bromley E, Richardson-Harman N, Pallansch LA, Lackman-Smith C, Osterling C, Mankowski M, Miller SR, Catalone BJ, Welsh PA, Howett MK, Wigdahl B, Turpin JA, Reichelderfer P: **In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories.** *Antimicrob Agents Chemother* 2006, **50(2)**:713-723.
  24. Cohen MS: **Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis.** *Lancet* 1998, **351(Suppl 3)**:5-7.
  25. Briggs DR, Tuttle DL, Sleasman JW, Goodenow MM: **Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages).** *Aids* 2000, **14(18)**:2937-2939.
  26. Shattock RJ, Moore JP: **Inhibiting sexual transmission of HIV-1 infection.** *Nat Rev Microbiol* 2003, **1(1)**:25-34.
  27. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD: **Genotypic and phenotypic characterization of HIV-1 patients with primary infection.** *Science* 1993, **261(5125)**:1179-1181.
  28. van't Wout AB, Kootstra NA, Mulder-Kampinga GA, Albrecht-van Lent N, Scherpier HJ, Veenstra J, Boer K, Coutinho RA, Miedema F, Schuitemaker H: **Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.** *J Clin Invest* 1994, **94(5)**:2060-2067.
  29. Shattock RJ, Doms RW: **AIDS models: microbicides could learn from vaccines.** *Nat Med* 2002, **8(5)**:425.
  30. Van Damme L, Wright A, Depraetere K, Rosenstein I, Vandersmissen V, Poulter L, McKinlay M, Van Dyck E, Weber J, Profy A, Laga M, Kitchen V: **A phase I study of a novel potential intravaginal microbicide, PRO in healthy sexually inactive women.** *Sex Transm Infect* 2000, **76(2)**:126-130.
  31. Lacey CJ, Wright A, Weber JN, Profy AT: **Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study.** *Aids* 2006, **20(7)**:1027-1030.
  32. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgreffe S, La Franco-Scheuch L, Compton L, Duan L, Shore MD, Zupancic M, Busch M, Carlis J, Wolinsky S, Haase AT: **Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus.** *J Virol* 2005, **79(14)**:9217-9227.
  33. Miller CJ, Shattock RJ: **Target cells in vaginal HIV transmission.** *Microbes Infect* 2003, **5(1)**:59-67.
  34. Turville SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, Miranda-Saksena M, Dable J, Stossel H, Romani N, Piatak M Jr, Lifson JD, Pope M, Cunningham AL: **Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells.** *Blood* 2004, **103(6)**:2170-2179.
  35. Nobile C, Petit C, Moris A, Skrabal K, Abastado JP, Mammano F, Schwartz O: **Covert human immunodeficiency virus replication in dendritic cells and in DC-SIGN-expressing cells promotes long-term transmission to lymphocytes.** *J Virol* 2005, **79(9)**:5386-5399.
  36. Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, Ratnam V, Doncel GF: **Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicide contraceptives.** *Biol Reprod* 2004, **71(3)**:761-769.
  37. Mayer KH, Karim SA, Kelly C, Maslankowski L, Rees H, Profy AT, Day J, Welch J, Rosenberg Z: **Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women.** *Aids* 2003, **17(3)**:321-329.
  38. Cheshenko N, Keller MJ, MasCasullo V, Jarvis GA, Cheng H, John M, Li JH, Hogarty K, Anderson RA, Waller DP, Zaneveld LJ, Profy AT, Klotman ME, Herold BC: **Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread.** *Antimicrob Agents Chemother* 2004, **48(6)**:2025-2036.
  39. Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A, Goldberg CL, Wallenstein S, Profy AT, Klotman ME, Herold BC: **PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.** *J Infect Dis* 2006, **193(1)**:27-35.
  40. Gong E, Matthews B, McCarthy T, Chu J, Holan G, Raff J, Sacks S: **Evaluation of dendrimer SPL 7013, a lead microbicide candidate against herpes simplex viruses.** *Antiviral Res* 2005, **68(3)**:139-146.
  41. Yim KC, Carroll CJ, Tuyama A, Cheshenko N, Carlucci MJ, Porter DD, Prince GA, Herold BC: **The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies.** *J Virol* 2005, **79(23)**:14632-14639.
  42. Potts B: **Mini Reverse Transcriptase (RT) Assay.** In *Techniques in HIV Research* Edited by: Walker Aa. New York/London: Stockton Press/Macmillan Publishers Ltd; 1990.
  43. Herold BC, WuDunn D, Soltys N, Spear PG: **Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity.** *J Virol* 1991, **65(3)**:1090-1098.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

